From the Journals

Red-cell donor’s sex does not affect transfusion survival


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Big data

Commenting on the study, Jeannie Callum, MD, professor and director of transfusion medicine at Queen’s University, Kingston, Ont., said that the use of routinely collected data from the participating hospitals’ electronic medical records was “one of the really great things about this paper.”

This use of Big Data “allows you to do a trial like this with almost 9,000 patients without spending millions and millions of dollars to have people go through charts and record data,” she added.

Dr. Callum also pointed out some of the trial’s limitations. “One of the things that kind of detracts from the study in my mind is that they randomized everybody that was getting a transfusion, but outpatients getting a transfusion have a very low mortality rate. So, you have a group of patients that are never going to have that endpoint being included in the study, and that might’ve diluted the findings.”

About 11.4% of participants received blood from a donor group other than the one to which they had been assigned, and this factor may further dilute the findings, said Dr. Callum. “That’s a difficult thing to avoid.” She noted that a trial in which she is collaborating, called Sex Matters, may answer some of these questions about the use of female versus male donor blood.

The investigators also noted that the findings may not be generalizable to other countries. “Just because we didn’t find something in Canada with our blood production system doesn’t mean that the United States might not find it different, because how they manufacture their red blood cells for transfusion is different than how we do them in Canada,” said Dr. Callum.

Nonetheless, this study shows the potential of using Big Data in medicine. “This is the future of large randomized clinical trials to quickly answer questions,” said Dr. Callum. “In the United States, Canada, and other countries that have these large electronic medical records systems, this kind of trial would be able to be done in other centers.”

The study was funded by the Canadian Institutes of Health Research. Dr. Fergusson and Dr. Callum disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Global effort needed to widen access to HSCT
MDedge Hematology and Oncology
Post-transplant diet: Gruel no longer rules
MDedge Hematology and Oncology
‘Astonishing’ results: Skip salvage chemo, proceed to HSCT
MDedge Hematology and Oncology
MCL: Ibrutinib could become the ‘new standard’
MDedge Hematology and Oncology
‘Exciting’: Post-SCT, antiviral T-cell therapy shows promise
MDedge Hematology and Oncology
Pound of flesh buys less prison time
MDedge Hematology and Oncology
Transplant vs. chemo: Similar AML survival rates
MDedge Hematology and Oncology
Inclusive reminder: LGBTQ community may donate stem cells
MDedge Hematology and Oncology
Erythema extent predicts death in cutaneous GVHD
MDedge Hematology and Oncology
Financial navigators saved about $2,500 per cancer patient
MDedge Hematology and Oncology